EXEL vs. BMY

In the year-to-date period, EXEL achieves a 10.66% return, which is significantly higher than BMY's -0.20% return. Over the past 10 years, EXEL has outperformed BMY with an annualized return of 30.00%, while BMY has yielded a comparatively lower 2.23% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current EXEL Sharpe Ratio is 2.34, which is higher than the BMY Sharpe Ratio of 0.60. The chart below compares the historical Sharpe Ratios of EXEL and BMY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

EXEL has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.33%.

The maximum EXEL drawdown since its inception was -97.38%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for EXEL and BMY. For additional features, visit the drawdowns tool.

Exelixis, Inc. (EXEL) has a higher volatility of 10.70% compared to Bristol-Myers Squibb Company (BMY) at 8.69%. This indicates that EXEL's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Exelixis, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.